Home › Gilead Sciences tops 3Q earnings and revenue expectations
 

Keywords :   


Gilead Sciences tops 3Q earnings and revenue expectations

2015-10-28 12:51:57| Biotech - Topix.net

Propelled by skyrocketing sales of its breakthrough hepatitis C pills, Gilead Sciences Inc. posted an impressive 68 per cent increase in third-quarter profit and hiked its revenue forecast yet again. The Forest City, California, company has what amounts to a license to print money in its Harvoni, the first once-daily, single-pill regimen for hepatitis C, and predecessor drug Sovaldi, both launched in the last two years.

Tags: sciences revenue expectations tops

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.09Atlantic Tropical Weather Outlook
28.09Eastern North Pacific Tropical Weather Outlook
28.09Hurricane Isaac Forecast Discussion Number 9
28.09Post-Tropical Cyclone Helene Graphics
28.09Post-Tropical Cyclone Helene Public Advisory Number 19
28.09Tropical Storm Joyce Graphics
28.09Hurricane Isaac Graphics
28.09Hurricane Isaac Wind Speed Probabilities Number 9
More »